3/13
08:13 pm
nvs
Novartis AGM Links Board Refresh And Dividend Growth To Future Returns [Yahoo! Finance]
Neutral
Report
Novartis AGM Links Board Refresh And Dividend Growth To Future Returns [Yahoo! Finance]
3/13
02:01 pm
nvs
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa [Yahoo! Finance]
Low
Report
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa [Yahoo! Finance]
3/13
09:29 am
nvs
Peanut Allergy Market Analysis Report 2025-2035: PALFORZIA and Xolair Approvals, Improved Diagnosis and Innovative Drug Delivery Platforms Drive Growth [Yahoo! Finance]
Low
Report
Peanut Allergy Market Analysis Report 2025-2035: PALFORZIA and Xolair Approvals, Improved Diagnosis and Innovative Drug Delivery Platforms Drive Growth [Yahoo! Finance]
3/11
08:04 pm
nvs
Lilly unveils $3 billion production expansion in China [Yahoo! Finance]
Low
Report
Lilly unveils $3 billion production expansion in China [Yahoo! Finance]
3/11
08:42 am
nvs
Novartis (NVS) was upgraded by Argus from "hold" to "buy". They now have a $180.00 price target on the stock.
Low
Report
Novartis (NVS) was upgraded by Argus from "hold" to "buy". They now have a $180.00 price target on the stock.
3/10
12:01 pm
nvs
Sandoz creates biosimilar unit to benefit from major patent cliff [Seeking Alpha]
Low
Report
Sandoz creates biosimilar unit to benefit from major patent cliff [Seeking Alpha]
3/10
09:45 am
nvs
Odyssey Therapeutics Appoints H. Martin Seidel, Ph.D., to Scientific Advisory Board [Yahoo! Finance]
Low
Report
Odyssey Therapeutics Appoints H. Martin Seidel, Ph.D., to Scientific Advisory Board [Yahoo! Finance]
3/7
07:03 pm
nvs
Novartis Advances Immunology And Oncology Plans As Valuation Gap Persists [Yahoo! Finance]
Low
Report
Novartis Advances Immunology And Oncology Plans As Valuation Gap Persists [Yahoo! Finance]
3/6
02:48 pm
nvs
Novartis AG (NVS) Shareholder/Analyst Call Prepared Remarks Transcript [Seeking Alpha]
Low
Report
Novartis AG (NVS) Shareholder/Analyst Call Prepared Remarks Transcript [Seeking Alpha]
3/6
10:53 am
nvs
Servier to buy Day One Biopharma for $2.5 billion in tumor treatment push [Yahoo! Finance]
Low
Report
Servier to buy Day One Biopharma for $2.5 billion in tumor treatment push [Yahoo! Finance]
3/6
08:51 am
nvs
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting [Yahoo! Finance]
Low
Report
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting [Yahoo! Finance]
3/3
03:09 pm
nvs
Hematologic Malignancies Market to Reach USD 128.48 Billion by 2032, Driven by Immunotherapy, CAR-T, and Precision Oncology - Credence Research Inc. [Yahoo! Finance]
Low
Report
Hematologic Malignancies Market to Reach USD 128.48 Billion by 2032, Driven by Immunotherapy, CAR-T, and Precision Oncology - Credence Research Inc. [Yahoo! Finance]
3/3
10:08 am
nvs
Forget Amarin: This Oft-Overlooked Pharma Powerhouse Is a Better Buy Now [Yahoo! Finance]
Low
Report
Forget Amarin: This Oft-Overlooked Pharma Powerhouse Is a Better Buy Now [Yahoo! Finance]
3/3
07:29 am
nvs
Beacon Therapeutics appoints Ryan Robinson as Chief Financial Officer [Yahoo! Finance]
Low
Report
Beacon Therapeutics appoints Ryan Robinson as Chief Financial Officer [Yahoo! Finance]
2/28
02:32 am
nvs
Novartis (NVS) Announces Plans to Establish a New Radioligand Therapy Manufacturing Site in Denton, Texas [Yahoo! Finance]
Low
Report
Novartis (NVS) Announces Plans to Establish a New Radioligand Therapy Manufacturing Site in Denton, Texas [Yahoo! Finance]
2/27
08:53 pm
nvs
OCT West Coast: China's clinical trial infrastructure delivers upto 60% cost savings [Yahoo! Finance]
Low
Report
OCT West Coast: China's clinical trial infrastructure delivers upto 60% cost savings [Yahoo! Finance]
2/27
09:12 am
nvs
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy [Yahoo! Finance]
Low
Report
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy [Yahoo! Finance]
2/27
07:01 am
nvs
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU) [Yahoo! Finance]
Low
Report
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU) [Yahoo! Finance]
2/26
07:02 pm
nvs
Novartis selects Denton for new factory as part of $23 billion US expansion [Yahoo! Finance]
Medium
Report
Novartis selects Denton for new factory as part of $23 billion US expansion [Yahoo! Finance]
2/26
11:26 am
nvs
Nonprofit models support strategic boldness to develop gene therapies for rare diseases [Yahoo! Finance]
Low
Report
Nonprofit models support strategic boldness to develop gene therapies for rare diseases [Yahoo! Finance]
2/25
05:10 pm
nvs
Assessing Novartis (SWX:NOVN) Valuation After Positive Phase III Data And Upcoming Regulatory Milestones [Yahoo! Finance]
Low
Report
Assessing Novartis (SWX:NOVN) Valuation After Positive Phase III Data And Upcoming Regulatory Milestones [Yahoo! Finance]
2/25
07:56 am
nvs
Novartis to build radioligand therapy site in Texas to expand US manufacturing [Yahoo! Finance Canada]
Low
Report
Novartis to build radioligand therapy site in Texas to expand US manufacturing [Yahoo! Finance Canada]
2/25
07:53 am
nvs
Novartis to build radioligand therapy site in Texas to expand US manufacturing [Yahoo! Finance]
Low
Report
Novartis to build radioligand therapy site in Texas to expand US manufacturing [Yahoo! Finance]
2/25
07:18 am
nvs
Slate Medicines raises $130m in funds to progress anti-PACAP treatments [Yahoo! Finance]
Low
Report
Slate Medicines raises $130m in funds to progress anti-PACAP treatments [Yahoo! Finance]
2/25
07:00 am
nvs
Novartis to build new radioligand therapy site in Denton, Texas, delivering more next-generation treatments to patients
Low
Report
Novartis to build new radioligand therapy site in Denton, Texas, delivering more next-generation treatments to patients